ArticleAmerican journal of respiratory and critical care medicine2020
Endothelial HIF-2α as a Key Endogenous Mediator Preventing Emphysema.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Allele-specific control of rodent and human lncRNA KMT2E-AS1 promotes hypoxic endothelial pathology in pulmonary hypertension.Science translational medicine · 2024Pooled it
- Modelling cigarette smoke-induced lung vascular dysfunction using an alveolus-on-chip.Materials today. Bio · 2026Article
- Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits.Respiratory research · 2025Review
- Article
- Oxidative Stress and Inflammation in Hypoxemic Respiratory Diseases and Their Comorbidities: Molecular Insights and Diagnostic Advances in Chronic Obstructive Pulmonary Disease and Sleep Apnea.Antioxidants (Basel, Switzerland) · 2025Review
- Experimental Mouse Models and Human Lung Organoid Models for Studying Chronic Obstructive Pulmonary Disease.Biomolecules & therapeutics · 2024Review
- Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.Journal of aerosol medicine and pulmonary drug delivery · 2024Review
- Chronic diesel exhaust exposure induced pulmonary vascular remodeling a potential trajectory for traffic related pulmonary hypertension.Respiratory research · 2024Article
- Multiple applications of metal-organic frameworks (MOFs) in the treatment of orthopedic diseases.Frontiers in bioengineering and biotechnology · 2024Review
- Pulmonary Vasodilator Therapy in Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (Severe PH-COPD): A Systematic Review and Meta-Analysis.Journal of cardiovascular development and disease · 2023Review
- Review
- Endotyping COPD: hypoxia-inducible factor-2 as a molecular "switch" between the vascular and airway phenotypes?European respiratory review : an official journal of the European Respiratory Society · 2023Review
- A pH-responsive metal-organic framework for the co-delivery of HIF-2α siRNA and curcumin for enhanced therapy of osteoarthritis.Journal of nanobiotechnology · 2023Article
- Pericytes: The lung-forgotten cell type.Frontiers in physiology · 2023Review
- Effects of hypoxia on bronchial and alveolar epithelial cells linked to pathogenesis in chronic lung disorders.Frontiers in physiology · 2023Article
- Cigarette smoke-induced airspace disease in mice develops independently of HIF-1α signaling in leukocytes.American journal of physiology. Lung cellular and molecular physiology · 2022Article
- Exploring disease interrelationships in patients with lymphatic disorders: A single center retrospective experience.Clinical and translational medicine · 2022Article
- Review
- Transcription factors in the pathogenesis of pulmonary arterial hypertension-Current knowledge and therapeutic potential.Frontiers in cardiovascular medicine · 2022Review
- Hypoxia and Hypoxia-Inducible Factors in Lymphedema.Frontiers in pharmacology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 3 institutions in 1 country.
Shravani PasupnetiVeterans Affairs Palo Alto Health Care System, Palo Alto, California.ORCID 0000-0002-7112-601X
Wen TianVeterans Affairs Palo Alto Health Care System, Palo Alto, California.
Allen B TuVeterans Affairs Palo Alto Health Care System, Palo Alto, California.
Petra DahmsVeterans Affairs Palo Alto Health Care System, Palo Alto, California.
Eric GranucciVeterans Affairs Palo Alto Health Care System, Palo Alto, California.
Aneta GandjevaSchool of Medicine, University of Colorado, Colorado; and.
Menglan XiangVeterans Affairs Palo Alto Health Care System, Palo Alto, California.
Eugene C ButcherVeterans Affairs Palo Alto Health Care System, Palo Alto, California.
Gregg L SemenzaVascular Program, Institute for Cell Engineering.
Rubin M TuderSchool of Medicine, University of Colorado, Colorado; and.
Xinguo JiangVeterans Affairs Palo Alto Health Care System, Palo Alto, California.
Mark R NicollsVeterans Affairs Palo Alto Health Care System, Palo Alto, California.
VA Palo Alto Health Care System · USUniversity of Colorado Denver · USJohns Hopkins University · US
Funding
VRAC and Rho in pulmonary EC proliferationP01HL014985 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI STENMARK, KURT R. · 1985 to 2019
$35.1MPulmonary Hypertension in Genetically Modified MiceR01HL074186 · NHLBI · STANFORD UNIVERSITY · PI RABINOVITCH, MARLENE · 2004 to 2022
$10.4MPulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1MEndothelial Injury, BMPR2 Dysfunction and Macrophage Activation Cause EndMT and PAHR01HL138473 · NHLBI · STANFORD UNIVERSITY · PI Mark Robert Nicolls, Marlene Rabinovitch · 2017 to 2026
$4.9MCritical Role for Microvasculature in Airway TransplantationR01HL095686 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI NICOLLS, MARK ROBERT · 2010 to 2022
$4.7MStanford Training Program in Lung BiologyT32HL129970 · NHLBI · STANFORD UNIVERSITY · PI CORNFIELD, DAVID N., NICOLLS, MARK ROBERT · 2016 to 2025
$3.2MA Critical Role for Leukotriene B4 in LymphedemaR01HL141105 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI NICOLLS, MARK ROBERT · 2019 to 2022
$2.3MPredoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2MStanford Career Development Program in Omics of Lung DiseasesK12HL120001 · NHLBI · STANFORD UNIVERSITY · PI NICOLLS, MARK ROBERT, RABINOVITCH, MARLENE · 2013 to 2017
$1.3MNHLBI NIH HHS K12 HL120001NHLBI NIH HHS P01 HL014985NHLBI NIH HHS R01 HL074186NHLBI NIH HHS R01 HL095686NHLBI NIH HHS R01 HL141105NHLBI NIH HHS R24 HL123767NHLBI NIH HHS T32 HL129970NIGMS NIH HHS T32 GM099608
Abstract
PubMed holds no abstract for this paper.
Indexed as
Angiogenesis InhibitorsAnimalsBasic Helix-Loop-Helix ProteinsDeferoxamineDisease Models, AnimalEndothelial CellsEndothelial PAS Domain-Containing Protein 1Hepatocyte Growth FactorHumansHypoxia-Inducible Factor 1, alpha SubunitIndolesIron Chelating AgentsLungMiceMice, KnockoutMicrovesselsAngiogenesis InhibitorsBasic Helix-Loop-Helix ProteinsDeferoxamineEndothelial PAS Domain-Containing Protein 1Hepatocyte Growth FactorHif1a protein, mouseHypoxia-Inducible Factor 1, alpha SubunitIndolesIron Chelating AgentsPyrrolesSemaxinibSmokeemphysemahepatocyte growth factorhypoxia-inducible factor-2α
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.